Shattuck Labs (STTK) Competitors

Shattuck Labs (NASDAQ:STTK) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Does the media prefer STTK or NVCT?

In the previous week, Shattuck Labs had 9 more articles in the media than Nuvectis Pharma. MarketBeat recorded 11 mentions for Shattuck Labs and 2 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.70 beat Shattuck Labs' score of 0.68 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Do analysts rate STTK or NVCT?

Shattuck Labs currently has a consensus target price of $7.50, suggesting a potential upside of 604.23%. Nuvectis Pharma has a consensus target price of $15.00, suggesting a potential upside of 44.93%. Given Shattuck Labs' higher probable upside, equities analysts clearly believe Shattuck Labs is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.71
Nuvectis Pharma	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer STTK or NVCT?

Shattuck Labs received 28 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 91.67% of users gave Nuvectis Pharma an outperform vote while only 69.64% of users gave Shattuck Labs an outperform vote.

Company	Underperform	Outperform
Shattuck Labs	Outperform Votes 39 69.64%	Underperform Votes 17 30.36%
Nuvectis Pharma	Outperform Votes 11 91.67%	Underperform Votes 1 8.33%

Which has preferable valuation and earnings, STTK or NVCT?

Nuvectis Pharma has lower revenue, but higher earnings than Shattuck Labs. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$6.44M	7.90	-$87.30M	-$1.53	-0.70
Nuvectis Pharma	N/A	N/A	-$22.26M	-$1.11	-9.32

Do institutionals & insiders hold more shares of STTK or NVCT?

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 10.5% of Shattuck Labs shares are owned by insiders. Comparatively, 35.8% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more volatility and risk, STTK or NVCT?

Shattuck Labs has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.

Is STTK or NVCT more profitable?

Nuvectis Pharma has a net margin of 0.00% compared to Shattuck Labs' net margin of -1,156.46%. Shattuck Labs' return on equity of -61.92% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	-1,156.46%	-61.92%	-54.49%
Nuvectis Pharma	N/A	-155.80%	-104.02%

Summary

Shattuck Labs and Nuvectis Pharma tied by winning 9 of the 18 factors compared between the two stocks.